In vivo monitoring of staphylococcus aureus biofilm infections and antimicrobial therapy by [18F] Fluoro-Deoxyglucose-MicroPET in a Mouse Model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6660-6667

  Garrido, Victoria ^a   Collantes, María ^b   Barberán, Montserrat ^c   Peñuelas, Iván ^b,d   Arbizu, Javier ^d   Amorena, Beatriz ^a   Grilló, María Jesús ^a  

^a CSIC   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSIDAD DE ZARAGOZA   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; FLUORODEOXYGLUCOSE F 18; HEMATOXYLIN; RIFAMPICIN; ANTIINFECTIVE AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL KINETICS; CATHETER INFECTION; CLINICAL EVALUATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FEMALE; FIBROBLAST; FOAM CELL; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ANIMAL; BACTERIUM ADHERENCE; BIOFILM; DISEASE MODEL; DRUG EFFECTS; INDWELLING CATHETER; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOFILMS; CATHETERS, INDWELLING; DISEASE MODELS, ANIMAL; FEMALE; FLUORODEOXYGLUCOSE F18; MICE; MICROBIAL SENSITIVITY TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84908577559     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03138-14     Document Type: Article

References (36)

1. Cucarella C, Solano C, Valle J, Amorena B, Lasa I, Penades JR. 2001. Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J. Bacteriol. 183:2888-2896. http://dx.doi.org/10.1128/JB.183.9.2888-2896 .2001.
2. Valle J, Vergara-Irigaray M, Merino N, Penades JR, Lasa I. 2007. SigmaB regulates IS256-mediated Staphylococcus aureus biofilm phenotypic variation. J. Bacteriol. 189:2886-2896. http://dx.doi.org/10.1128/JB.01767-06.
3. Heilmann C, Gerke C, Perdreau-Remington F, Gotz F. 1996. Characterization of Tn917 insertion mutants of Staphylococcus epidermidis affected in biofilm formation. Infect. Immun. 64:277-282.
4. Cramton SE, Gerke C, Schnell NF, Nichols WW, Gotz F. 1999. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect. Immun. 67:5427-5433.
5. McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Doring G, Lee JC, Goldmann DA, Pier GB. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284:1523-1527. http://dx.doi.org/10.1126/science.284.5419.1523.
6. Vergara-Irigaray M, Valle J, Merino N, Latasa C, Garcia B, Ruiz de Los Mozos I, Solano C, Toledo-Arana A, Penades JR, Lasa I. 2009. Relevant role of fibronectin-binding proteins in Staphylococcus aureus biofilmassociated foreign-body infections. Infect. Immun. 77:3978-3991. http://dx.doi.org/10.1128/IAI.00616-09.
7. Christner M, Franke GC, Schommer NN, Wendt U, Wegert K, Pehle P, Kroll G, Schulze C, Buck F, Mack D, Aepfelbacher M, Rohde H. 2010. The giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectin. Mol. Microbiol. 75:187-207. http://dx.doi.org/10.1111/j.1365-2958 .2009.06981.x.
8. Pozzi C, Waters EM, Rudkin JK, Schaeffer CR, Lohan AJ, Tong P, Loftus BJ, Pier GB, Fey PD, Massey RC, O'Gara JP. 2012. Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog. 8:e1002626. http://dx.doi.org/10.1371/journal.ppat.1002626.
9. Laverty G, Gorman SP, Gilmore BF. 2013. Biomolecular mechanisms of staphylococcal biofilm formation. Future Microbiol. 8:509-524. http://dx.doi.org/10.2217/fmb.13.7.
10. Kadurugamuwa JL, Sin L, Albert E, Yu J, Francis K, DeBoer M, Rubin M, Bellinger-Kawahara C, Parr TR, Jr, Contag PR. 2003. Direct continuous method for monitoring biofilm infection in a mouse model. Infect. Immun. 71:882-890. http://dx.doi.org/10.1128/IAI.71.2.882-890.2003.
11. Merino N, Toledo-Arana A, Vergara-Irigaray M, Valle J, Solano C, Calvo E, Lopez JA, Foster TJ, Penades JR, Lasa I. 2009. Protein A-mediated multicellular behavior in Staphylococcus aureus. J. Bacteriol. 191: 832-843. http://dx.doi.org/10.1128/JB.01222-08.
12. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Kimura R, Purchio T, Contag PR. 2003. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. Antimicrob. Agents Chemother. 47:3130-3137. http://dx.doi.org/10.1128/AAC.47.10.3130-3137 .2003.
13. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Purchio TF, Contag PR. 2004. Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo. Antimicrob. Agents Chemother. 48: 2283-2287. http://dx.doi.org/10.1128/AAC.48.6.2283-2287.2004.
14. Dinjaski N, Suri S, Valle J, Lehman SM, Lasa I, Prieto MA, Garcia AJ. 2014. Near-infrared fluorescence imaging as an alternative to bioluminescent bacteria to monitor biomaterial-associated infections. Acta Biomater. 10:2935-2944. http://dx.doi.org/10.1016/j.actbio.2014.03.005.
15. Israel O, Keidar Z. 2011. PET/CT imaging in infectious conditions. Ann. N. Y. Acad. Sci. 1228:150-166. http://dx.doi.org/10.1111/j.1749-6632 .2011.06026.x.
16. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, Israel O, Martin-Comin J, Signore A. 2013. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J. Nucl. Med. 54:647-658. http://dx.doi.org/10.2967/jnumed.112.112524.
17. Catana C, Procissi D, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Jacobs RE, Cherry SR. 2008. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc. Natl. Acad. Sci. U. S. A. 105: 3705-3710. http://dx.doi.org/10.1073/pnas.0711622105.
18. Lankinen P, Lehtimaki K, Hakanen AJ, Roivainen A, Aro HT. 2012. A comparative 18F-FDG PET/CT imaging of experimental Staphylococcus aureus osteomyelitis and Staphylococcus epidermidis foreign-bodyassociated infection in the rabbit tibia. EJNMMI Res. 2:41. http://dx.doi.org/10.1186/2191-219X-2-41.
19. Koort JK, Makinen TJ, Knuuti J, Jalava J, Aro HT. 2004. Comparative 18F-FDG PET of experimental Staphylococcus aureus osteomyelitis and normal bone healing. J. Nucl. Med. 45:1406-1411.
20. Toledo-Arana A, Merino N, Vergara-Irigaray M, Debarbouille M, Penades JR, Lasa I. 2005. Staphylococcus aureus develops an alternative, ica-independent biofilm in the absence of the arlRS two-component system. J. Bacteriol. 187:5318-5329. http://dx.doi.org/10.1128/JB.187.15 .5318-5329.2005.
21. Valle J, Toledo-Arana A, Berasain C, Ghigo JM, Amorena B, Penades JR, Lasa I. 2003. SarA and not sigmaB is essential for biofilm development by Staphylococcus aureus. Mol. Microbiol. 48:1075-1087. http://dx.doi.org/10.1046/j.1365-2958.2003.03493.x.
22. Tormo MA, Ubeda C, Marti M, Maiques E, Cucarella C, Valle J, Foster TJ, Lasa I, Penades JR. 2007. Phase-variable expression of the biofilmassociated protein (Bap) in Staphylococcus aureus. Microbiology 153: 1702-1710. http://dx.doi.org/10.1099/mic.0.2006/005744-0.
23. Cucarella C, Tormo MA, Ubeda C, Trotonda MP, Monzon M, Peris C, Amorena B, Lasa I, Penades JR. 2004. Role of biofilm-associated protein bap in the pathogenesis of bovine Staphylococcus aureus. Infect. Immun. 72:2177-2185. http://dx.doi.org/10.1128/IAI.72.4.2177-2185.2004.
24. Amorena B, García de Jalón JA, Baselga R, Ducha J, Latre MV, Ferrer LM, Sancho F, Mansson I, Krovacek Faris KA. 1991. Experimental infection in mammary glands with ovine mastitis bacterial strains: evaluation of a rabbit model. J. Comp. Pathol. 104:289-302. http://dx.doi.org/10.1016/S0021-9975(08)80041-2.
25. Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, Vogel WV, Peeters MJ. 2010. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 37: 1069-1076. http://dx.doi.org/10.1007/s00259-009-1343-2.
26. Murray PR, Baron EJ, Jorgensen JH, Phaller MA, Yolken RH. 2003. Manual of clinical microbiology, 8th ed. ASM, Press, Washington, DC.
27. Gamelli RL, Liu H, He LK, Hofmann CA. 1996. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J. Leukoc. Biol. 59:639-647.
28. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, Hosokawa M, Kohanawa M, Tamaki N. 2001. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J. Nucl. Med. 42:1551-1555.
29. Cucarella C, Tormo MA, Knecht E, Amorena B, Lasa I, Foster TJ, Penades JR. 2002. Expression of the biofilm-associated protein interferes with host protein receptors of Staphylococcus aureus and alters the infective process. Infect. Immun. 70:3180-3186. http://dx.doi.org/10.1128/IAI .70.6.3180-3186.2002.
30. Valle J, Latasa C, Gil C, Toledo-Arana A, Solano C, Penades JR, Lasa I. 2012. Bap, a biofilm matrix protein of Staphylococcus aureus prevents cellular internalization through binding to GP96 host receptor. PLoS Pathog. 8:e1002843. http://dx.doi.org/10.1371/journal.ppat.1002843.
31. Eardley WG, Martin KR, Taylor C, Kirkman E, Clasper JC, Watts SA. 2012. The development of an experimental model of contaminated muscle injury in rabbits. Int. J. Low. Extrem. Wounds 11:254-263.
32. Monzon M, Oteiza C, Leiva J, Lamata M, Amorena B. 2002. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn. Microbiol. Infect. Dis. 44:319-324. http://dx.doi.org/10.1016/S0732-8893(02)00464-9.
33. Amorena B, Gracia E, Monzon M, Leiva J, Oteiza C, Perez M, Alabart JL, Hernandez-Yago J. 1999. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J. Antimicrob. Chemother. 44:43-55. http://dx.doi.org/10.1093/jac/44.1.43.
34. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50: 55-61. http://dx.doi.org/10.1128/AAC.50.1.55-61.2006.
35. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR. 2010. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur. J. Clin. Microbiol. Infect. Dis. 29:961-967. http://dx.doi.org/10.1007/s10096-010-0952-9.
36. Achermann Y, Eigenmann K, Ledergerber B, Derksen L, Rafeiner P, Clauss M, Nuesch R, Zellweger C, Vogt M, Zimmerli W. 2013. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection 41:431-437. http://dx.doi.org/10.1007/s15010-012-0325-7.